Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis

American Journal of Gastroenterology

Volumn 104, Issue 2, 2009, Pages 437-443

  Miele, Erasmo ^a   Pascarella, Filomena ^a   Giannetti, Eleonora ^a   Quaglietta, Lucia ^a   Baldassano, Robert N ^b   Staiano, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; METHYLPREDNISOLONE; PLACEBO; VSL3;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; BACTERIAL STRAIN; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOSCOPY; ENTERITIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MALE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SCHOOL CHILD; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; COLONOSCOPY; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; PROBIOTICS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 59749088586     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2008.118     Document Type: Article

References (39)

1. Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am 1999;28:445-58.
2. Tibble AJ, Sigthorsson G, Bridger B et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000 ;19 :51-22.
3. Turner D, Walsh CM, Benchimol EI et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut 2008;57:331-8.
4. Hyams J, Markowitz J, Lerer T et al. Pediatric Inflammatory Bowel Disease Collaborative Research Group. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 2006;4 :1118-23.
5. Fuller R. A review: probiotics in man and animals. J Appl Bacteriol 1989;66:365-78.
6. Mallon P, McKay D, Kirk S et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;(4):CD005573.
7. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008 ;134 :577-49.
8. Gionchetti P, Lammers KM, Rizzello F et al. VSL#3: an analysis of basic and clinical contributions in probiotic therapeutics. Gastroenterol Clin North Am 2005;34:499-513.
9. Caballero-Franco C, Keller K, De Simone C et al. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 2007;292:G315-22.
10. Soo I, Madsen KL, Tejpar Q et al. VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation. Can J Gastroenterol 2008;22:237-42.
11. Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo controlled trial. Gastroenterology 2000 ;119 :305-9.
12. Mimura T, Rizzello F, Helwig U et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-14.
13. Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-9.
14. Venturi A, Gionchetti P, Rizzello F et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103-8.
15. Bibiloni R, Fedorak RN, Tannok G et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539-46.
16. Hildebrand HF, Holmquist B, Kristiansson L et al. Chronic inflammatory bowel disease in children and adolescents in Sweden. J Pediatr Gastroenterol Nutr 1991;13:293-7.
17. Tiplady B. A basic program for constructing a dispensing list for a randomized clinical trial. Br J Clin Pharmacol 1981;11:617-8.
18. Lichtiger S, Present D, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Eng J Med 1994;330:1841-5.
19. Russell GH, katz AJ. Infliximab is effective in acute but no chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr 2004;39:166-70.
20. Rutter M, Saunders B, Wilkinson K et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-9.
21. Heyman MB, Kirschner BS, Gold BD et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005 ;146 :35-40.
22. Wehkamp J, Stange EF.A new look at Crohn's disease: breakdown of the mucosal antibacterial defense. Ann NY Acad Sci 2006;1072:321-31.
23. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126:1620-33.
24. Marteau P, Shanahan F. Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract Res Clin Gastroenterol 2003;17:725-40.
25. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008 ;134 :577-94.
26. Isolauri E, Juntunen M, Rautanen T et al. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 1991;88:90-7.
27. Schultz M, Veltkamp C, Dieleman LA et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-defcient mice. Inflamm Bowel Dis 2002;8:71-80.
28. Madsen KL, Doyle JS, Jewell LD et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:1107-14.
29. Fabia R, Ar'Rajab A, Johannsson ML et al. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat. Scand J Gastroenterol 1993;28:155-62.
30. Kruis W, Fric P, Pokrotnieks J et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-23.
31. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15:697-8.
32. Rembacken BJ, Snelling AM, Hawkey PM et al. Eshcherichia coli vs. mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999;354:635-9.
33. Kato K, Mizuno S, Umesaki Y et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004;20:1133-41.
34. Tursi A, Brandimarte G, Giorgetti GM et al. Low dose balsalazide plus a high potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acutemild-to-moderate ulcerative colitis. Med Sci Monit 2004;10:126-31.
35. Furrie E, Macfarlane S, Kennedy A et al. Synbiotic therapy (Bfidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005;54:242-9.
36. Madsen K, Cornish A, Soper P et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121:580-91.
37. Shibolet O, Karmeli F, Eliakim R. Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis 2002;8:399-406.
38. Rachmilewitz D, Karmeli F, Takabayashi K et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002;122:1428-41.
39. Rachmilewitz D, Katakura K, Karmeli F et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004 ;126 :520-8.